Pieris Pharmaceuticals Stock Price, News & Analysis (NASDAQ:PIRS)

$8.56 -0.07 (-0.81 %)
(As of 02/21/2018 10:49 AM ET)
Previous Close$8.56
Today's Range$8.50 - $9.02
52-Week Range$1.88 - $9.75
Volume841,700 shs
Average Volume874,685 shs
Market Capitalization$433.27 million
P/E Ratio-11.48
Dividend YieldN/A
Beta1.74

About Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998

Debt

Debt-to-Equity RatioN/A
Current Ratio2.44%
Quick Ratio2.44%

Price-To-Earnings

Trailing P/E Ratio-11.4795746003432
Forward P/E Ratio-13.81
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.83 million
Price / Sales73.72
Cash FlowN/A
Price / CashN/A
Book Value$0.59 per share
Price / Book14.51

Profitability

Trailing EPS($0.74)
Net Income$-22,790,000.00
Net Margins-321.83%
Return on Equity-221.93%
Return on Assets-42.02%

Miscellaneous

Employees52
Outstanding Shares50,210,000

Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) announced its quarterly earnings results on Wednesday, November, 8th. The biotechnology company reported ($0.16) EPS for the quarter, beating the Zacks' consensus estimate of ($0.21) by $0.05. The biotechnology company earned $3.93 million during the quarter, compared to analysts' expectations of $1.52 million. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The firm's revenue was up 400.3% compared to the same quarter last year. View Pieris Pharmaceuticals' Earnings History.

Where is Pieris Pharmaceuticals' stock going? Where will Pieris Pharmaceuticals' stock price be in 2018?

4 equities research analysts have issued 12-month price targets for Pieris Pharmaceuticals' shares. Their forecasts range from $9.00 to $12.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $10.00 in the next twelve months. View Analyst Ratings for Pieris Pharmaceuticals.

Who are some of Pieris Pharmaceuticals' key competitors?

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the folowing people:

  • James A. Geraghty, Chairman of the Board (Age 62)
  • Stephen S. Yoder, President, Chief Executive Officer, Director (Age 39)
  • Lance E. Thibault, Acting Chief Financial Officer (Age 50)
  • Claude Knopf, Senior Vice President, Chief Business Officer
  • Louis A. Matis M.D., Senior Vice President and Chief Development Officer (Age 54)
  • Julian Adams, Director (Age 61)
  • Jean-Pierre Bizzari M.D., Director (Age 62)
  • Christopher P. Kiritsy, Director (Age 49)
  • Steven Prelack, Independent Director (Age 57)
  • Michael Richman, Independent Director (Age 54)

Who owns Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (5.86%), Tekla Capital Management LLC (4.38%), BlackRock Inc. (3.56%), Omega Fund Management LLC (2.02%), Sphera Funds Management LTD. (1.79%) and Millennium Management LLC (1.56%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis, Orbimed Advisors Llc and Stephen S Yoder. View Institutional Ownership Trends for Pieris Pharmaceuticals.

Who sold Pieris Pharmaceuticals stock? Who is selling Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, BVF Inc. IL, Omega Fund Management LLC, Sphera Funds Management LTD., EAM Investors LLC and Rhumbline Advisers. View Insider Buying and Selling for Pieris Pharmaceuticals.

Who bought Pieris Pharmaceuticals stock? Who is buying Pieris Pharmaceuticals stock?

Pieris Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Millennium Management LLC, Renaissance Technologies LLC, Vident Investment Advisory LLC, Goldman Sachs Group Inc., Deutsche Bank AG, Strs Ohio and Geode Capital Management LLC. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis and Stephen S Yoder. View Insider Buying and Selling for Pieris Pharmaceuticals.

How do I buy Pieris Pharmaceuticals stock?

Shares of Pieris Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of Pieris Pharmaceuticals stock can currently be purchased for approximately $8.56.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $433.27 million and generates $5.83 million in revenue each year. The biotechnology company earns $-22,790,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Pieris Pharmaceuticals employs 52 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]


MarketBeat Community Rating for Pieris Pharmaceuticals (PIRS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  197
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pieris Pharmaceuticals (NASDAQ:PIRS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.00$10.00$9.00$8.25
Price Target Upside: 25.16% upside44.51% upside64.53% upside78.19% upside

Pieris Pharmaceuticals (NASDAQ:PIRS) Consensus Price Target History

Price Target History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ:PIRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/9/2018HC WainwrightSet Price TargetBuy$12.00HighView Rating Details
1/17/2018William BlairInitiated CoverageOutperformHighView Rating Details
5/30/2017Rodman & RenshawInitiated CoverageBuy -> Buy$9.00HighView Rating Details
4/12/2017OppenheimerSet Price TargetBuy$9.00LowView Rating Details
9/28/2016Roth CapitalReiterated RatingBuy$6.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$10.00 -> $9.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Pieris Pharmaceuticals (NASDAQ:PIRS) Earnings History and Estimates Chart

Earnings by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ PIRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.21)($0.16)$1.52 million$3.93 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.14)($0.23)$3.75 million$1.85 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.16($0.19)$32.30 million$1.34 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.13)($0.16)$1.10 million$2.73 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.13)($0.14)$1.12 million$0.79 millionViewN/AView Earnings Details
8/10/2016Q216($0.15)($0.14)$1.08 million$1.07 millionViewN/AView Earnings Details
5/11/2016Q116($0.12)($0.10)$6.40 million$1.25 millionViewN/AView Earnings Details
3/23/2016Q415($0.12)($0.07)$3.27 million$2.14 millionViewN/AView Earnings Details
11/11/2015Q315($0.11)($0.10)$0.23 million$0.42 millionViewN/AView Earnings Details
8/12/2015Q215($0.14)($0.12)$0.25 million$0.16 millionViewN/AView Earnings Details
5/13/2015Q1 2015($0.19)($0.13)$1.00 million$0.22 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Pieris Pharmaceuticals (NASDAQ:PIRS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.78)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.23)($0.15)($0.19)
Q2 20182($0.22)($0.17)($0.20)
Q3 20182($0.20)($0.18)($0.19)
Q4 20182($0.21)($0.19)($0.20)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Pieris Pharmaceuticals (NASDAQ:PIRS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.05%
Institutional Ownership Percentage: 52.16%
Insider Trades by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)
Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Orbimed Advisors LlcMajor ShareholderSell7,897$8.98$70,915.06View SEC Filing  
1/3/2018Orbimed Advisors LlcMajor ShareholderSell1,709,620$7.35$12,565,707.00View SEC Filing  
12/18/2017Orbimed Advisors LlcMajor ShareholderSell147,635$5.70$841,519.50View SEC Filing  
8/17/2017Allan ReineInsiderBuy65,000$4.82$313,300.0045,000View SEC Filing  
8/17/2017James A GeraghtyDirectorBuy10,000$4.82$48,200.0010,000View SEC Filing  
6/14/2016Louis MatisSVPBuy10,000$1.70$17,000.002,085View SEC Filing  
6/13/2016Darlene M Deptula-HicksCFOBuy5,000$1.66$8,300.005,000View SEC Filing  
6/13/2016Stephen S YoderCEOBuy6,000$1.68$10,080.006,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pieris Pharmaceuticals (NASDAQ PIRS) News Headlines

Source:
DateHeadline
 Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) Will Announce Quarterly Sales of $7.63 Million Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) Will Announce Quarterly Sales of $7.63 Million
www.americanbankingnews.com - February 20 at 11:32 AM
Pieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare ConferencePieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 19 at 5:09 PM
BidaskClub Lowers Pieris Pharmaceuticals (PIRS) to BuyBidaskClub Lowers Pieris Pharmaceuticals (PIRS) to Buy
www.americanbankingnews.com - February 17 at 11:40 AM
Pieris Pharmaceuticals (PIRS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowPieris Pharmaceuticals (PIRS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:17 PM
Stock Traders Buy Large Volume of Pieris Pharmaceuticals Put Options (PIRS)Stock Traders Buy Large Volume of Pieris Pharmaceuticals Put Options (PIRS)
www.americanbankingnews.com - February 16 at 6:58 AM
Pieris Pharmaceuticals Inc (PIRS) Major Shareholder Orbimed Advisors Llc Sells 7,897 SharesPieris Pharmaceuticals Inc (PIRS) Major Shareholder Orbimed Advisors Llc Sells 7,897 Shares
www.americanbankingnews.com - February 15 at 10:04 PM
Pieris Pharma (PIRS) Prices 5.5M Share Common Offering at $8/ShPieris Pharma (PIRS) Prices 5.5M Share Common Offering at $8/Sh
www.streetinsider.com - February 15 at 9:19 AM
Pieris Pharmaceuticals Inc (PIRS) Receives Consensus Recommendation of "Buy" from AnalystsPieris Pharmaceuticals Inc (PIRS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 14 at 3:26 PM
Pieris Pharma (PIRS) Plans Public Offering of Common StockPieris Pharma (PIRS) Plans Public Offering of Common Stock
www.streetinsider.com - February 14 at 9:52 AM
Pieris Pharmaceuticals Announces Public Offering of Common StockPieris Pharmaceuticals Announces Public Offering of Common Stock
finance.yahoo.com - February 14 at 9:52 AM
Pieris Pharmaceuticals Announces Pricing of its Public OfferingPieris Pharmaceuticals Announces Pricing of its Public Offering
finance.yahoo.com - February 14 at 9:52 AM
Seattle Genetics (SGEN), Pieris Pharmaceuticals (PIRS) Announce Multi-Program Immuno-Oncology Pact - StreetInsider.comSeattle Genetics (SGEN), Pieris Pharmaceuticals (PIRS) Announce Multi-Program Immuno-Oncology Pact - StreetInsider.com
www.streetinsider.com - February 11 at 3:55 PM
Pieris Pharmaceuticals: Management Continues To Execute - Seeking AlphaPieris Pharmaceuticals: Management Continues To Execute - Seeking Alpha
seekingalpha.com - February 11 at 3:55 PM
Pieris Pharmaceuticals (PIRS) Given a $12.00 Price Target at HC WainwrightPieris Pharmaceuticals (PIRS) Given a $12.00 Price Target at HC Wainwright
www.americanbankingnews.com - February 9 at 2:16 PM
Why Pieris Pharmaceuticals Inc. Is Soaring TodayWhy Pieris Pharmaceuticals Inc. Is Soaring Today
www.fool.com - February 9 at 12:59 PM
Pieris Pharmaceuticals Inc to Post Q1 2018 Earnings of ($0.15) Per Share, William Blair Forecasts (PIRS)Pieris Pharmaceuticals Inc to Post Q1 2018 Earnings of ($0.15) Per Share, William Blair Forecasts (PIRS)
www.americanbankingnews.com - February 9 at 8:00 AM
Pieris Pharmaceuticals (PIRS) Rating Increased to Hold at ValuEnginePieris Pharmaceuticals (PIRS) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - February 4 at 5:35 PM
Is Pieris Pharmaceuticals Inc (NASDAQ:PIRS) As Financially Strong As Its Balance Sheet Indicates?Is Pieris Pharmaceuticals Inc (NASDAQ:PIRS) As Financially Strong As Its Balance Sheet Indicates?
finance.yahoo.com - February 2 at 3:48 PM
Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6thPieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th
finance.yahoo.com - January 29 at 9:43 AM
Pieris Pharmaceuticals Inc (PIRS) Given Average Rating of "Buy" by BrokeragesPieris Pharmaceuticals Inc (PIRS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 20 at 5:38 PM
William Blair Weighs in on Pieris Pharmaceuticals Incs FY2017 Earnings (PIRS)William Blair Weighs in on Pieris Pharmaceuticals Inc's FY2017 Earnings (PIRS)
www.americanbankingnews.com - January 19 at 10:40 AM
$3.59 Million in Sales Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter$3.59 Million in Sales Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter
www.americanbankingnews.com - January 17 at 4:46 PM
Pieris Artificial Protein Platform Is Undervalued By The Street, Analyst SaysPieris' Artificial Protein Platform Is Undervalued By The Street, Analyst Says
www.msn.com - January 17 at 4:35 PM
 Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) to Announce -$0.14 EPS Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) to Announce -$0.14 EPS
www.americanbankingnews.com - January 15 at 5:38 AM
Insider Selling: Pieris Pharmaceuticals Inc (PIRS) Major Shareholder Sells 1,709,620 Shares of StockInsider Selling: Pieris Pharmaceuticals Inc (PIRS) Major Shareholder Sells 1,709,620 Shares of Stock
www.americanbankingnews.com - January 4 at 7:04 PM
Zacks: Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) to Announce -$0.14 Earnings Per ShareZacks: Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) to Announce -$0.14 Earnings Per Share
www.americanbankingnews.com - December 29 at 9:30 AM
Pieris Pharmaceuticals (PIRS) Upgraded to Buy at BidaskClubPieris Pharmaceuticals (PIRS) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - December 28 at 3:26 PM
Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session - NasdaqPieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session - Nasdaq
www.nasdaq.com - December 27 at 9:57 PM
Pieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in SessionPieris Pharmaceuticals (PIRS) Soars: Stock Adds 15.2% in Session
finance.yahoo.com - December 27 at 4:56 PM
ETFs with exposure to Pieris Pharmaceuticals, Inc. : December 27, 2017ETFs with exposure to Pieris Pharmaceuticals, Inc. : December 27, 2017
finance.yahoo.com - December 27 at 4:56 PM
Pieris Pharma (PIRS) Doses First Healthy Subjects in Phase I Study of PRS-060 - StreetInsider.comPieris Pharma (PIRS) Doses First Healthy Subjects in Phase I Study of PRS-060 - StreetInsider.com
www.streetinsider.com - December 21 at 10:22 AM
Pieris Pharmaceuticals Inc (PIRS) Major Shareholder Sells $841,519.50 in StockPieris Pharmaceuticals Inc (PIRS) Major Shareholder Sells $841,519.50 in Stock
www.americanbankingnews.com - December 20 at 5:38 PM
Pieris Pharmaceuticals (PIRS) Given a $9.00 Price Target at HC WainwrightPieris Pharmaceuticals (PIRS) Given a $9.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 20 at 11:28 AM
Pieris Pharmaceuticals (PIRS) vs. The Competition Head-To-Head ReviewPieris Pharmaceuticals (PIRS) vs. The Competition Head-To-Head Review
www.americanbankingnews.com - December 19 at 9:32 AM
Comparing Pieris Pharmaceuticals (PIRS) and Its RivalsComparing Pieris Pharmaceuticals (PIRS) and Its Rivals
www.americanbankingnews.com - December 19 at 7:14 AM
 Analysts Expect Pieris Pharmaceuticals Inc (PIRS) Will Announce Quarterly Sales of $3.59 Million Analysts Expect Pieris Pharmaceuticals Inc (PIRS) Will Announce Quarterly Sales of $3.59 Million
www.americanbankingnews.com - December 14 at 6:50 PM
4 Top-Ranked Biotech Stocks Under $20 With Room for Growth4 Top-Ranked Biotech Stocks Under $20 With Room for Growth
finance.yahoo.com - December 14 at 10:32 AM
Zacks: Analysts Expect Pieris Pharmaceuticals Inc (PIRS) to Post -$0.14 EPSZacks: Analysts Expect Pieris Pharmaceuticals Inc (PIRS) to Post -$0.14 EPS
www.americanbankingnews.com - December 12 at 5:06 AM
Pieris Pharma (PIRS) Announces Ethics, Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory ... - StreetInsider.comPieris Pharma (PIRS) Announces Ethics, Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory ... - StreetInsider.com
www.streetinsider.com - December 9 at 4:30 PM
Pieris Pharmaceuticals (PIRS) & Its Rivals Critical ComparisonPieris Pharmaceuticals (PIRS) & Its Rivals Critical Comparison
www.americanbankingnews.com - December 7 at 7:28 PM
Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402Pieris Pharmaceuticals Announces Ethics and Regulatory Clearance to Begin Clinical Testing of Inhaled Respiratory Program, PRS-060/AZD1402
finance.yahoo.com - December 7 at 10:47 AM
Pieris Pharmaceuticals (PIRS) and Its Rivals Critical ReviewPieris Pharmaceuticals (PIRS) and Its Rivals Critical Review
www.americanbankingnews.com - December 4 at 3:18 PM
Pieris Pharmaceuticals (PIRS) Rating Lowered to Sell at ValuEnginePieris Pharmaceuticals (PIRS) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 2 at 9:10 PM
Pieris Pharmaceuticals, Inc. (PIRS) Receives Consensus Rating of "Buy" from BrokeragesPieris Pharmaceuticals, Inc. (PIRS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 1 at 11:56 PM
ETFs with exposure to Pieris Pharmaceuticals, Inc. : November 30, 2017ETFs with exposure to Pieris Pharmaceuticals, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 4:31 PM
Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Pieris Pharmaceuticals, Inc. :PIRS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:29 AM
Contrasting Pieris Pharmaceuticals (PIRS) & Ardelyx (ARDX)Contrasting Pieris Pharmaceuticals (PIRS) & Ardelyx (ARDX)
www.americanbankingnews.com - November 26 at 3:48 AM
Pieris Pharma (PIRS) Names James Geraghty as Board Chairman - StreetInsider.comPieris Pharma (PIRS) Names James Geraghty as Board Chairman - StreetInsider.com
www.streetinsider.com - November 23 at 7:29 AM
Pieris Pharmaceuticals (PIRS) vs. The Competition Head-To-Head SurveyPieris Pharmaceuticals (PIRS) vs. The Competition Head-To-Head Survey
www.americanbankingnews.com - November 22 at 11:10 PM
First Week Of January 2018 Options Trading For Pieris Pharmaceuticals (PIRS)First Week Of January 2018 Options Trading For Pieris Pharmaceuticals (PIRS)
www.thestreet.com - November 22 at 6:41 AM

SEC Filings

Pieris Pharmaceuticals (NASDAQ:PIRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pieris Pharmaceuticals (NASDAQ:PIRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pieris Pharmaceuticals (NASDAQ PIRS) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.